Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Mammalian muscle" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mammalian Cardiac Muscle Tissue. Muscle is the contractile tissue of animals, which functions in the production of both voluntary and involuntary movements. The three basic types of muscle are striated, smooth, and cardiac. Comprised of elongated cells with multiple nuclei, cardiac muscle tissue appears striated under the microscope.
Aligned scaffolding system for skeletal muscle regeneration
Provided herein are anisotropic muscle implants that have a biodegradable scaffold comprising a plurality of fibers oriented along a longitudinal axis. The implants may include mammalian muscle cells seeded and / or fused into myotubes on the scaffold. Methods of forming the muscle implants are provided, as are methods of treating a subject in need of skeletal muscle reconstruction.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Methods and Systems for Submucosal Implantation of a Device for Diagnosis and Treatment of a Body
Instruments, systems and methods are provided for performing submucosal medical procedures in a desired area of the digestive tract using endoscopy. Instruments include a safe access needle injection instrument, a submucosal tunneling instrument, a submucosal dissection instrument, and a mucosal resection device. Systems include a combination of one or more of such instruments with or without injectable agents. Embodiments of various methods for performing the procedures are also provided. In accordance with one aspect there is provided a submucosal implant device for diagnosing and treating disorders of the body. The submucosal implant device may take the form of a gastric stimulator in which signals are supplied to the muscular wall of a mammal to treat motility disorders. In accordance with yet another aspect there is provided a method for performing a submucosal medical procedure to deploy a submucosal implant device in the digestive tract of a mammal.
Owner:APOLLO ENDOSURGERY INC
Muscle regeneration compositions and uses therefor
InactiveUS20070190056A1Function increaseQuality improvementPeptide/protein ingredientsGenetic material ingredientsSarcopeniaMammalian muscle
The present invention relates to a method of treating and / or ameliorating one or more symptoms of sarcopenia and age-related muscle degeneration in a mammal.
Owner:ORICO
Polynucleotide herpes virus vaccine
InactiveUS7094767B2Avoid infectionAmeliorate HSV-related diseaseSugar derivativesGenetic material ingredientsMammalSeroconversion
Genes encoding herpes simplex virus type 2 (HSV-2) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. In a DNA titration, it was found that a single immunization of ≧0.5 μg of (one) PNV, gave >90% seroconversion by ten weeks post immunization. Immune antisera neutralized both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p<0.001) protection from lethal infection was achieved following PNV vaccination. DNA constructs may be full-length, truncated and / or mutated forms and may be delivered along or in combination in order to optimize immunization and protection from HSV infection.
Owner:MERCK SHARP & DOHME CORP
System and method for intra-body communication
InactiveUS20100305437A1Ultrasonic/sonic/infrasonic diagnosticsElectrotherapyEngineeringMammalian muscle
A method comprising generating a mechanical signal in a mammal, the mechanical signal having a frequency no more than 50,000 Hz, transmitting the mechanical signal through the musculoskeletal system in the mammal, and sensing the mechanical signal from the musculoskeletal system. A method of triggering an internal event comprising generating a mechanical signal internal or external to a mammal, transmitting the signal through the musculoskeletal system of the mammal, detecting the mechanical signal, and triggering an event in response to the mechanical signal. A method of drug delivery comprising generating a mechanical signal internal or external to a mammal, transmitting the signal through the musculoskeletal system of the mammal, detecting the mechanical signal, and delivering the drug in response to the mechanical signal.
Owner:LIEBSCHNER MICHAEL +3
Aligned scaffolding system for skeletal muscle regeneration
Provided herein are anisotropic muscle implants that have a biodegradable scaffold comprising a plurality of fibers oriented along a longitudinal axis. The implants may include mammalian muscle cells seeded and / or fused into myotubes on the scaffold. Methods of forming the muscle implants are provided, as are methods of treating a subject in need of skeletal muscle reconstruction.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Detection and isolation of cell populations from muscle using antibodies to fa1/dlk1
InactiveUS20050221392A1Increase differentiationArtificial cell constructsVertebrate cellsProgenitorMuscle tissue
The present invention relates to the use of antibodies recognizing Fetal Antigen-1 (FA1 / dlk1) for the detection and isolation of cell populations in mammalian muscle. In one embodiment, myogenic progenitor cells are detected in developing, diseased or regenerating muscle. In another embodiment, muscle stem and progenitor myogenic progenitor cells are isolated from muscle tissue or from cultures containing muscle cells. The isolated cells may be used for transplantation, drug screening, production of cell type specific antibodies, and gene therapy and discovery. Transplantation of these cells may provide treatments for degenerative diseases of muscle, and for regeneration of muscle following trauma or ischemia such as myocardial infarction.
Owner:NSGENE AS
Method of co-culturing mammalian muscle cells and motoneurons
The invention provides a method of co-culturing mammalian muscle cells and mammalian motoneurons. The method comprises preparing one or more carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (DETA); suspending isolated fetal mammalian skeletal muscle cells in serum-free medium according to medium composition 1; suspending isolated fetal mammalian spinal motoneurons in serum-free medium according to medium composition 1; plating the suspended muscle cells onto the one or more carriers at a predetermined density and allowing the muscle cells to attach; plating the suspended motoneurons at a predetermined density onto the one or more carriers and allowing the motoneurons to attach; covering the one or more carriers with a mixture of medium composition 1 and medium composition 2; and incubating the carriers covered in the media mixture.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Methods for promoting wound healing and muscle regeneration with the cell signaling protein Nell1
The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.
Owner:UT BATTELLE LLC
Method for culturing skeletal muscle for tissue engineering
ActiveUS9163216B1Small sizeReduce complexityCulture processNervous system cellsInsulin-like growth factorSerum free media
The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Method of increasing the efficacy of neurotoxin
InactiveUS20080063732A1Good curative effectImproved therapeutic responseBiocidePeptide/protein ingredientsPhysical therapySweat gland
The present invention provides a method of increasing the efficacy of treating a muscle or sweat gland hyperactivity condition in a human or mammal with a neurotoxin. The method includes adding a quantity of either a diffusion-limiting agent or an anti-metabolic agent to the neurotoxin. Adding the agent to the neurotoxin leads to the formation of an agent / neurotoxin injection mixture. The quantity of agent added is sufficient to increase a therapeutic response of the human or mammal's sweat gland or muscle to the neurotoxin compared to what the response would have been had the human or mammal been treated with neurotoxin alone. The present invention provides a kit for treating a muscle or sweat gland hyperactivity condition in a human or mammal. The kit includes a needle, a solvent, a neurotoxin, and either a diffusion-limiting agent or an anti-metabolic agent.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Processed water and therepeutic uses thereof
InactiveUS20060286176A1Reduce the amount requiredBiocideInorganic active ingredientsMammalTreatment use
A physiologically ingestible composition of matter obtained by using water tuned to target certain pathologies in mammals, and uses thereof are provided. The tuned water is produced by passing the water through a plurality of coil sets in fluid communication. The tuned water may be used for producing and tuning super-oxygenated and structured water. The physiologically ingestible composition of matter may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Methods for Promoting Wound Healing and Muscle Regeneration with the Cell Signaling Protein Nell1
The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.
Owner:UT BATTELLE LLC
Chemical compounds and use thereof for improving muscular quality
ActiveUS20170226151A1Improve muscle qualityHigh strengthAmphibious vehiclesOrganic active ingredientsChemical compoundPhysiology
Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and / or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and / or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and / or preventing of obesity and associated complications and / or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
Owner:BIOPHYTIS +1
Derivatives used in the treatment of muscle atrophy
The invention relates to a derivative of general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and / or prevention of muscle atrophy in mammals and / or to limit muscle atrophy in mammals and / or to stimulate muscle growth in mammals doing exercise and aiming to increase muscle mass and quality, as prevention against the onset of age-related symptoms of sarcopenia or for rehabilitation following muscle loss, muscle atrophy being related to age and / or to the consequences of drug treatment and / or immobilisation and / or cachexia.
Owner:METABRAIN RES
Nutritional composition for stimulating muscle protein synthesis
ActiveCN103079415BGood for healthImprove exercise effectOrganic active ingredientsVitamin food ingredientsMuscle strengthMammal
The present invention relates to the use of stimulators of anabolic amino acid derivatives acting in combination with vitamin D in the preparation for the prevention and / or treatment of any of muscle mass, muscle strength, muscle function and body function, or any combination thereof, in mammals Loss of use in pharmaceutical or nutritional compositions.
Owner:NV NUTRICIA
Mammalian muscle-derived stem cells
ActiveUS10633633B2Minimally invasive characterSimple methodCell dissociation methodsSkeletal disorderCell lineageMesenchymal stem cell
Owner:UNIV LIEGE
Method for increasing muscle mass and strength
ActiveUS10869843B2Improve athletic abilityAdd additional massHeavy metal active ingredientsOrganic active ingredientsHerbal supplementNutrition
Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.
Owner:CHEMI NUTRA
System and Method for Intra-Body Communication
Owner:LIEBSCHNER MICHAEL +3
Injectable bone substitutes for augmenting implant fixation
InactiveUS20180177912A1Surgical adhesivesPharmaceutical delivery mechanismMusculoskeletal impairmentInjectable bone
The invention relates to the use of a cyclic glycopeptide to enhance the resistance of a composition to one or more of a tensile, shear and torsional force, where the composition comprises a bone substitute powder, an aqueous liquid and the cyclic glycopeptide. The invention also relates to a composition for use in the treatment of a musculoskeletal disorder in a mammal receiving an implant to enhance bone re-growth for stabilization of the implant, and to a method for the use of the composition in treatment of the mammal. The composition comprises a bone substitute powder, an aqueous liquid and a cyclic glycopeptide.
Owner:BONE SUPPORT
Skeletal muscle regeneration promoter
ActiveUS20140234286A1Improve regenerative abilityPeptide/protein ingredientsMuscular disorderDiseaseMyopathy
Provided is a skeletal muscle regeneration promoter for a muscular disorder or myopathy comprising a chondroitinase as an active component, which skeletal muscle regeneration promoter enhances, when administered into a muscular fiber of a mammal with the muscular disorder or myopathy, the regeneration of such a muscular fiber. The above-mentioned chondroitinase degrades chondroitin sulfate that is present at the outer perimeter of the above-mentioned muscular fiber; and thereby inhibition of the regeneration of the muscular fiber by the above-mentioned chondroitin sulfate disappears, which makes it possible to enhance the regeneration and enlargement of such a muscular fiber.
Owner:SEIKAGAKU KOGYO CO LTD
Method for culturing skeletal muscle for tissue engineering
ActiveUS20160068812A1Small sizeReduce complexityCulture processNervous system cellsSerum free mediaInsulin-like growth factor
The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Processed water and therapeutic uses thereof
InactiveUS20060275402A1Reduce the amount requiredBiocidePeroxide active ingredientsEnvironmental engineeringOxygen
A physiologically ingestible composition of matter obtained by using tuned super-oxygenated and structured water having multiple attributes, and uses thereof are provided. The tuned super-oxygenated and structured water is produced by receiving oxygen enriched water into a coil system and passing the water therethrough, combining water output by the coil system with structured ozone, inputting the combined water and structured ozone to a multicoil system and passing the water therethrough, and outputting tuned super-oxygenated and structured water. The tuned super-oxygenated and structured water may also be utilized for producing and tuning super-oxygenated and structured water. The physiologically ingestible composition of matter may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Method of Co-Culturing Mammalian Muscle Cells and Motoneurons
ActiveUS20140302599A1Long-term survivalCulture processNervous system cellsSerum free mediaDiethylenetriamine
The invention provides a method of co-culturing mammalian muscle cells and mammalian motoneurons. The method comprises preparing one or more carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (DETA); suspending isolated fetal mammalian skeletal muscle cells in serum-free medium according to medium composition 1; suspending isolated fetal mammalian spinal motoneurons in serum-free medium according to medium composition 1; plating the suspended muscle cells onto the one or more carriers at a predetermined density and allowing the muscle cells to attach; plating the suspended motoneurons at a predetermined density onto the one or more carriers and allowing the motoneurons to attach; covering the one or more carriers with a mixture of medium composition 1 and medium composition 2; and incubating the carriers covered in the media mixture.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Processed water and therapeutic uses thereof
InactiveUS20060275397A1Reduce the amount requiredBiocideInorganic active ingredientsAlkaline waterElectrolysis
A physiologically ingestible composition of matter obtained by using super-oxygenated and structured water, and uses thereof are provided. The super-oxygenated and structured water is produced by receiving water from a source, preconditioning the water for electrolysis, performing electrolysis on the preconditioned water to produce alkaline water, combining the alkaline water with oxygen, spinning the alkaline water / oxygen combination, and outputting super-oxygenated and structured water. The physiologically ingestible composition of matter may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Composition and therapeutic uses thereof
InactiveUS20060275386A1Reduce the amount requiredBiocidePeroxide active ingredientsOxygenMammalian muscle
A physiologically ingestible composition with microstructured water having a negative oxidation reduction potential of at least −40, and uses thereof are provided. The composition may further included dissolved oxygen, which may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Processed water and therapeutic uses thereof
InactiveUS20060275444A1Reduce the amount requiredBiocidePeroxide active ingredientsEnvironmental engineeringOxygen
A physiologically ingestible composition of matter obtained by using super-oxygenated and structured water, and uses thereof are provided. The tuned super-oxygenated and structured water is produced by receiving oxygen enriched water into a coil system and passing the water therethrough, combining water output by the coil system with structured ozone, inputting the combined water and structured ozone to a multicoil system and passing the water therethrough, and outputting tuned super-oxygenated and structured water. The tuned super-oxygenated and structured water may also be utilized for producing and tuning super-oxygenated and structured water. The physiologically ingestible composition of matter may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Composition and therapeutic uses thereof
A physiologically ingestible composition with microstructured water essentially of hydrogen and oxygen atoms, and dissolved oxygen is used. The composition may further include dissolved oxygen, which may be present in an amount of 20 ppm to 150 ppm. The composition may further include microstructured water having a pH of at least 8.7. The physiologically ingestible composition may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Processed water and therapeutic uses thereof
InactiveUS20060275400A1Reduce the amount requiredBiocideInorganic active ingredientsPre treatmentOxygen
A physiologically ingestible composition of matter obtained by using super-oxygenated and structured water produced by spinning water and oxygen, and uses thereof are provided. The super-oxygenated and structured water is obtained by receiving preconditioned water, combining the preconditioned water with oxygen, passing the preconditioned water / oxygen combination through a cone system that spins the combination, and outputting super-oxygenated and structured water. The physiologically ingestible composition of matter may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Composition and therapeutic uses thereof
InactiveUS20060275382A1Reduce the amount requiredBiocideInorganic active ingredientsHydrogenDistilled water
A physiologically ingestible composition comprising microstructured water consisting essentially of hydrogen and oxygen atoms and having a vapor pressure different than double distilled water is used. The physiologically ingestible composition may be administered to reduce the amount of lactic acid / lactate produced in the muscle of a mammal undergoing stress.
Owner:BAGLEY DAVID
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com